Adjunctive support for patients with chronic kidney disease (CKD) stages 1–3, specifically targeting the reduction of uremic toxin accumulation through gut microbiome modulation. Indicated to support kidney function preservation and reduce systemic inflammation associated with early-stage CKD.
Mechanism of Action: A proprietary blend of targeted prebiotics and postbiotics that selectively inhibit the intestinal bacteria responsible for producing uremic toxins (specifically indoxyl sulfate and p-cresyl sulfate precursors). By modifying the gut-kidney axis, the product reduces the toxic metabolite load reaching the kidneys, supporting renal function and reducing inflammatory burden.
Key Differentiators:
- No comparable NHP product exists in the Canadian market targeting the gut-kidney axis
- Backed by European clinical data supporting reduction in uremic toxin markers
- Complementary to existing nephrology drug therapy — not a replacement
- Strong HCP recommendation potential given the growing CKD patient population in Canada
Target Prescriber: Nephrologists, internal medicine physicians, and family practitioners managing early-stage CKD patients
Patient Profile: Adults 45–75 with CKD stages 1–3, often presenting alongside hypertension and Type 2 diabetes
